Tarsus Pharmaceuticals, Inc.
TARS
Pozycja w akcjach
#4560
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Cena akcji
$70.82
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$3.31B
Zmiana (1 dzień)
-0.30%
Zmiana (1 rok)
3.08%
Kraj
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategoria
Healthcare
Historia ceny akcji dla Tarsus Pharmaceuticals, Inc. (TARS)
Najwyższa cena zamknięcia: $72.26 dnia 2026-10-01
Najniższa cena zamknięcia: $21.51 dnia 2020-10-01
Najniższa cena zamknięcia: $21.51 dnia 2020-10-01
Historia cen akcji firmy Tarsus Pharmaceuticals, Inc. od 2020 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
